Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Fulcrum Therapeutics (FULC) Depreciation and Depletion: 2018-2024

Historic Depreciation and Depletion for Fulcrum Therapeutics (FULC) over the last 7 years, with Dec 2024 value amounting to $1.6 million.

  • Fulcrum Therapeutics' Depreciation and Depletion fell 25.00% to $300,000 in Q3 2025 from the same period last year, while for Sep 2025 it was $1.4 million, marking a year-over-year decrease of 23.56%. This contributed to the annual value of $1.6 million for FY2024, which is 27.27% down from last year.
  • Per Fulcrum Therapeutics' latest filing, its Depreciation and Depletion stood at $1.6 million for FY2024, which was down 27.27% from $2.2 million recorded in FY2023.
  • Over the past 5 years, Fulcrum Therapeutics' Depreciation and Depletion peaked at $2.5 million during FY2021, and registered a low of $1.6 million during FY2024.
  • Over the past 3 years, Fulcrum Therapeutics' median Depreciation and Depletion value was $2.2 million (recorded in 2023), while the average stood at $2.1 million.
  • Per our database at Business Quant, Fulcrum Therapeutics' Depreciation and Depletion increased by 14.29% in 2020 and then decreased by 27.27% in 2024.
  • Yearly analysis of 5 years shows Fulcrum Therapeutics' Depreciation and Depletion stood at $2.4 million in 2020, then increased by 4.79% to $2.5 million in 2021, then fell by 4.02% to $2.4 million in 2022, then dropped by 8.86% to $2.2 million in 2023, then decreased by 27.27% to $1.6 million in 2024.